Innovent Biologics

Innovent Biologics reported H1 2026 revenue of RMB 8.6 billion (+45% YoY) and an IFRS net profit of RMB 1.3 billion (+50% YoY). Product revenue rose 57% to RMB 8.2 billion, supported by strong demand in oncology and chronic diseases, and cash holdings stood at RMB 30.2 billion. The company outlined a 2030 strategy with a revenue target of RMB 35–40 billion and a focus on becoming a global biopharma platform; the stock climbed to HK$112.7 and was the top performer in the Hang Seng. » More on de.investing.com

Spero Therapeutics secures exclusive global rights to SP001, an Fc-silent anti-CD40L antibody, except for Greater China where Innovent retains rights. Innovent receives an upfront payment plus up to about $1.1 billion in development, regulatory and sales milestones, plus tiered royalties. Spero plans a phase 2 study in IgG4‑associated disease in Q2 2027; Innovent is targeting early 2027 for a phase 2 study in Sjögren’s syndrome in China. SP001 has been tested in early studies and is designed to reduce platelet activation seen with earlier anti-CD40L antibodies. » More on de.investing.com

Spero obtains the exclusive global rights (excluding Greater China) to IBI355, an Fc-inactivated anti-CD40L antibody, from Innovent. Innovent will receive an upfront payment, milestone payments of up to about $1.1 billion and tiered royalties on net sales. Spero plans a phase 2 study in IgG4-associated diseases in Q2 2027; Innovent will initiate a phase 2 study for Sjögren’s syndrome in China. The transaction marks a strategic shift for Spero toward immunology and inflammatory diseases. » More on de.investing.com

Innovent has rapidly built nationwide market access for Mazdutide, the first dual GCG/GLP-1 receptor agonist, after its approval for obesity treatment in June 2025, benefiting from limited domestic competition through 2027. At the same time, the bispecific PD-1/IL-2 fusion protein IBI363 is driving international expansion: the first global phase 3 trial is under way, phase 1 data showed a median PFS of 9.3 months and an ORR of 36.7%. Innovent also completed an out-licensing deal with Takeda for multiple cancer drugs, with the deal’s commercial potential reaching up to $11.4 billion. » More on de.investing.com